Sumitomo Dainippon Pharma Co., Ltd.
50 articles about Sumitomo Dainippon Pharma Co., Ltd.
-
Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 2 Zella 201 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Acute Myeloid Leukemia at 62nd ASH Annual Meeting
12/5/2020
Additional Presentations Provide Updates on Development Programs for Investigational Agents TP-3654 and Dubermatinib
-
Drawbridge Health Announces Partnerships to Fuel Expansion in Japan
10/27/2020
Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. as well as a new research and development collaboration agreement.
-
Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Dubermatinib at ESMO 2020 Virtual Annual Congress
9/11/2020
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19
-
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
9/10/2020
Collaboration to Focus on Rare Genetic and Demyelinating Diseases, Including Lysosomal Storage Diseases
-
BehaVR Partners to Advance Virtual Reality for Social Anxiety Disorder
8/5/2020
BehaVR , a leading innovator of virtual reality digital wellness and digital therapeutics experiences, today announced that it has begun a new partnership aimed at leveraging virtual reality experienc
-
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
7/1/2020
Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and Development
-
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
-
Top Biopharma M&As in 2019
1/10/2020
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. -
Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance
12/30/2019
Sumitomo Dainippon Pharma and Roivant Sciences complete strategic alliance and formation of new company, Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma
-
Sumitovant will run as a wholly owned subsidiary of Sumitomo Dainippon Pharma.
-
Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
12/20/2019
POXEL SA and Sumitomo Dainippon Pharma Co., Ltd announced positive topline results from TIMES 2, a Phase 3 trial evaluating Imeglimin in combination with approved hypoglycemic therapies, and as a monotherapy, for the treatment of type 2 diabetes in Japan.
-
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
11/1/2019
The agreement was formally signed yesterday. -
Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma’s Transaction with Roivant Sciences
10/31/2019
Sumitomo Dainippon Pharma has committed to provide an initial $200 million, low-interest, interest-only, five-year term loan facility, with no repayments due until the end of the term
-
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
10/31/2019
Alliance will include Roivant's ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis
-
Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
10/31/2019
Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term
-
Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
9/6/2019
Parties have entered into a non-binding memorandum of understanding ("Memorandum"); a definitive agreement expected by the end of October 2019
-
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
7/2/2019
Boston Biomedical, Inc. announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma will be discontinued due to futility.
-
Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes
6/25/2019
Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile
-
Sumitomo Dainippon Pharma Adopts Veeva Vault RIM to Streamline Global Regulatory Submissions
6/25/2019
Leading Japanese pharmaceutical company standardizes on Vault Submissions and Vault Submissions Archive to speed submission development and health authority correspondence
-
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
7/25/2018
Study met its primary endpoint demonstrating fewer binge days per week with dasotraline versus placebo in the treatment of adults with moderate to severe binge eating disorder.